Dosage and Route of Administration of Neuroleptic Drugs During Different Phases of a Schizophrenic Illness

  • J. M. Kane
Conference paper

Abstract

Maintenance antipsychotic drug treatment has proven to be of enormous value in preventing psychotic relapse and rehospitalization, as well as in setting the stage for optimal vocational and psychosocial adjustment in patients with schizophrenia. Numerous double-blind, placebo-controlled trials support these conclusions, and several review articles have appeared in recent years summarizing their findings (Davis et al. 1980; Kane and Lieberman 1987).

Keywords

Placebo Titration Schizophrenia Hydrochloride Haloperidol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986) The Northwick Park study of first episodes of schizophrenia. II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148:120–127PubMedCrossRefGoogle Scholar
  2. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70–87PubMedGoogle Scholar
  3. Hogarty GE, Schooler NR, Ulrich RF, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36:1283–1294PubMedCrossRefGoogle Scholar
  4. Kane J (1985) Compliance issues in outpatient treatment. J Clin Psychopharmacol 5:22S–27SPubMedCrossRefGoogle Scholar
  5. Kane JM, Borenstein M (1985) Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull 21:23–27PubMedGoogle Scholar
  6. Kane JM, Lieberman JA (1987) Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 1103–1109Google Scholar
  7. Kane JM, Rifkin A, Quitkin F, Nayak DV, Ramos-Lorenzi JR (1982) Fluphenazine versus placebo in patients with remitted, acute first episodes of schizophrenia. Arch Gen Psychiatry 39:70–73PubMedCrossRefGoogle Scholar
  8. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramo-Lorenzi J (1983) Low-dose neuroleptics in the treatment of outpatient schizophrenics. I. Relapse rates, preliminary results. Arch Gen Psychiatry 40:893–896PubMedCrossRefGoogle Scholar
  9. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22(l):254–258PubMedGoogle Scholar
  10. Marder SR, van Putten T, Mintz J, McKenzie J, Labelle M, Faltico G, May PRA (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41:1025–1029PubMedCrossRefGoogle Scholar
  11. May PRA, Tuma AH, Yale C, Potepan P, Dixson WJ (1976) Schizophrenia — a follow-up study of results of treatment. II. Hospital stay over 2–5 years. Arch Gen Psychiatry 33:481–486PubMedCrossRefGoogle Scholar
  12. McEvoy JP, Hogerty GE, Steingard S (1990) Optimal dose of neuroleptics in acute schizophrenia: a controlled study of the neuroleptic threshold. (Submitted for publication)Google Scholar
  13. Rabiner CJ, Wegner JT, Kane JM (1986) Outcome study of first-episode psychosis. I. Relapse rates afte one year. Am J Psychiatry 143:1155–1158PubMedGoogle Scholar
  14. Rifkin A, Quitkin F, Rabiner CJ, Klein DF (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenics. Arch Gen Psychiatry 34:43–47PubMedCrossRefGoogle Scholar
  15. Saltz BL, Kane JM, Woerner M, Lieberman JA, Alvir J (1989) Prospective study of tardive dyskinesia in the elderly. Psychopharmacol Bull 25(l):52–59PubMedGoogle Scholar
  16. Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB (1980) Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 37:16–24PubMedCrossRefGoogle Scholar
  17. Weiden PJ, Mann JJ, Haas G, Mattson M, Francis A (1986) Clinical nonrecognition of drug-induced movement disorders: a cautionary study. Annual Meeting of the American Psychiatric Association, May, WashingtonGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • J. M. Kane

There are no affiliations available

Personalised recommendations